Therapeutics News and Research

RSS

Scripps Florida scientist receives grant from Landenberger Foundation for HIV research

A scientist on the Florida campus of The Scripps Research Institute has received funding from the Philadelphia-based Margaret Q. Landenberger Research Foundation.

27 Oct 2010

New International malaria research consortium to develop novel classes of antimalarials

Research teams from three academic institutions and two private sector companies on two continents have come together to form the International malaria research consortium for the development of novel classes of antimalarials. This bold initiative will develop novel classes of drugs against malaria, a deadly disease in desperate need of new treatments.

27 Oct 2010

Elan 2010 third quarter total revenue decreases 2% to $281.4 million

Elan Corporation, plc today reported its third quarter and first nine months 2010 financial results.

27 Oct 2010

New Australian start-up venture could lead to a revolution in personalized medicine

Pharmaceuticals that seek out cancerous cells and deliver treatments to them; imaging techniques that can help doctors detect diseases before the physical signs begin to appear; and medicines that are tailor-made for individual patients, are within the sights of an exciting new Australian start-up venture.

27 Oct 2010

MacroGenics, Pfizer enter global research collaboration and license agreement for DART products

MacroGenics, Inc., a leader in next-generation antibody platforms and therapeutics, announced today that it has entered into a global research collaboration and license agreement with Pfizer Inc. to discover, develop and commercialize Dual-Affinity Re-Targeting (DART) products directed at two undisclosed cancer targets.

27 Oct 2010

Boehringer Ingelheim and MacroGenics enter global antibody-based therapeutics alliance

Boehringer Ingelheim and MacroGenics today jointly announced that they have entered into a global alliance to discover, develop and commercialize antibody-based therapeutics which may span multiple therapeutic areas, including immunology, oncology, respiratory, cardiometabolic and infectious diseases.

27 Oct 2010

AutoGenomics granted FDA 510(k) clearance for INFINITI CYP2C19 Assay

AutoGenomics, a leader in providing automated, molecular testing solutions announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration to market its INFINITI® CYP2C19 Assay. The test detects 3 genetic variants, *2, *3, *17, of the CYP450 2C19 gene and is to be used on the company's automated molecular testing platform, the INFINITI® Analyzer.

27 Oct 2010

Purdue and Mundipharma assume worldwide development for Infinity's fatty acid amide hydrolase program

Infinity Pharmaceuticals, Inc. today announced that Purdue Pharmaceutical Products L.P. and its independent associated company, Mundipharma International Corporation Ltd., have exercised their right to assume worldwide development and commercialization activities for Infinity's fatty acid amide hydrolase, or FAAH, program. The decision reflects progress made in the development of Infinity's oral FAAH inhibitor, IPI-940.

26 Oct 2010

miRagen and CU enter agreement on miRNA therapeutics discovery and development

miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients' lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, and the University of Colorado (CU) announced today that they have entered into sponsored research and licensing agreements to collaborate on miRNA therapeutics discovery and development.

26 Oct 2010

Agile presents AG200-15 contraceptive patch Phase 2 clinical study results at 66th ASRM

Agile Therapeutics announced results today from a Phase 2 clinical study of AG200-15, Agile's weekly contraceptive patch containing ethinyl estradiol (EE) in combination with levonorgestrel (LNG). According to the clinical findings, AG200-15 provides a low daily dose of estrogen equivalent to 30 micrograms EE, similar to that in low-dose, oral contraceptive (OC) pills.

26 Oct 2010

Compugen 2010 third quarter net loss decreases to $1.6 million from $1.9 million

Compugen Ltd. today reported financial results for the third quarter ending September 30, 2010.

26 Oct 2010

Lumiphore signs global cooperation with Algeta to integrate Lumi4 complexes

Lumiphore Inc., a portfolio company of Nanostart AG, has signed a global cooperation with Algeta ASA a leading company specializing in innovative radiopharmaceutical therapies to treat cancer patients. The agreement enables the integration of Lumiphore's Lumi4 complexes into the targeted radiotherapeutics and companion diagnostics from Algeta.

From Thermo Fisher Scientific Inc. 26 Oct 2010

aTyr Pharma announces $23 million Series C equity financing

aTyr Pharma, the physiocrine therapeutics company, today announced a $23 million Series C equity financing led by Domain Associates. Domain joins existing venture investors Alta Partners, Cardinal Partners and Polaris Ventures, who also participated in the financing.

26 Oct 2010

Omeros to develop new drugs for major diseases

The Life Sciences Discovery Fund (LSDF) today announced a $5 million grant to Seattle-based Omeros Corporation (NASDAQ: OMER) to discover, develop, and commercialize new drugs to treat a variety of major diseases. With successful generation of proceeds through partnering and the sales of drugs in the marketplace, an additional outcome of the grant would be establishment of a new non-profit initiative to advance the life sciences sector and improve health and economic growth in Washington state.

26 Oct 2010

Innovative program for new graduate doctors to ensure safety prescription

A new software based program has recently been created for new graduate doctors to ensure they prescribe safely from day one on the wards.

26 Oct 2010

Celtic, Resolvyx enter option agreement for RX-10045 to treat dry eye syndrome

Celtic Therapeutics Holdings L.P. a successor firm to Celtic Pharma, and Resolvyx Pharmaceuticals, Inc. (Resolvyx) announced today that they have entered into an option agreement relating to Resolvyx's RX-10045, a late-stage program for the treatment of dry eye syndrome and other ophthalmic conditions.

26 Oct 2010

Trius receives patent protection for torezolid phosphate in the U.S.

Trius Therapeutics, Inc. announced today the issuance of Patent Number 7,816,379, entitled "Oxazolidinone Derivatives," by the United States Patent and Trademark Office (USPTO). The new patent, which is exclusively licensed to Trius, protects the Company's lead investigational drug, torezolid phosphate (TR-701), currently in Phase 3 clinical testing in patients with acute bacterial skin and skin structure infections (ABSSSI).

26 Oct 2010

TRACON to present data on TRC105, TRC102 cancer therapies at EORTC-NCI-AACR Symposium

TRACON Pharmaceuticals, a biotechnology company that develops targeted therapies for oncology and related diseases, announced today that new data on TRC105 and TRC102 will be presented at the 22nd Annual EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Berlin, Germany.

26 Oct 2010

Baxter announces launch of GLASSIA in the U.S.

Baxter International Inc. today announced the commercial launch of GLASSIATM [Alpha1-Proteinase Inhibitor (Human)] in the United States. GLASSIATM is the first available ready-to-use liquid alpha1-proteinase inhibitor (Alpha1-PI) and is indicated as a chronic augmentation and maintenance therapy in adults with emphysema due to congenital deficiency of alpha-1 antitrypsin (AAT), an under-diagnosed hereditary condition characterized by a low level of alpha-1 protein in the blood.

From Baxter International Inc. 26 Oct 2010

NIH awards Phase I SBIR grant to develop Generic Antibodies for cancer

Rockland Immunochemicals Inc., a biotechnology company focusing on antibodies and antibody based tools for basic research, diagnostic assay development and preclinical studies, today announced that it has received a Phase I Small Business Innovation Research (SBIR) grant from the National Institutes of Health to develop Generic Antibodies "Biosimilars" for the Treatment of Cancer.

26 Oct 2010

Therapeutics News and Research

Scripps Florida scientist receives grant from Landenberger Foundation for HIV research

New International malaria research consortium to develop novel classes of antimalarials

Elan 2010 third quarter total revenue decreases 2% to $281.4 million

New Australian start-up venture could lead to a revolution in personalized medicine

MacroGenics, Pfizer enter global research collaboration and license agreement for DART products

Boehringer Ingelheim and MacroGenics enter global antibody-based therapeutics alliance

AutoGenomics granted FDA 510(k) clearance for INFINITI CYP2C19 Assay

Purdue and Mundipharma assume worldwide development for Infinity's fatty acid amide hydrolase program

miRagen and CU enter agreement on miRNA therapeutics discovery and development

Agile presents AG200-15 contraceptive patch Phase 2 clinical study results at 66th ASRM

Compugen 2010 third quarter net loss decreases to $1.6 million from $1.9 million

Lumiphore signs global cooperation with Algeta to integrate Lumi4 complexes

aTyr Pharma announces $23 million Series C equity financing

Omeros to develop new drugs for major diseases

Innovative program for new graduate doctors to ensure safety prescription

Celtic, Resolvyx enter option agreement for RX-10045 to treat dry eye syndrome

Trius receives patent protection for torezolid phosphate in the U.S.

TRACON to present data on TRC105, TRC102 cancer therapies at EORTC-NCI-AACR Symposium

Baxter announces launch of GLASSIA in the U.S.

NIH awards Phase I SBIR grant to develop Generic Antibodies for cancer

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News